Monte Rosa Therapeutics Inc Forecast, price target & analysts
Monte Rosa Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Monte Rosa Therapeutics Inc Classifications & Recommendation
Monte Rosa Therapeutics Inc Price Target
| Target Price | $27.54 |
| Price | $11.77 |
| Potential |
133.99%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Monte Rosa Therapeutics Inc 2027 .
The average Monte Rosa Therapeutics Inc target price is $27.54.
This is
133.99%
register free of charge
$38.85
230.08%
register free of charge
$25.25
114.53%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend Monte Rosa Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Monte Rosa Therapeutics Inc stock has an average upside potential 2027 of
133.99%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 123.67 | 45.33 |
| 63.54% | 63.35% | |
| EBITDA Margin | -37.07% | -76.51% |
| 61.59% | 106.37% | |
| Net Margin | -31.24% | -350.33% |
| 67.51% | 1,021.55% |
9 Analysts have issued a sales forecast Monte Rosa Therapeutics Inc 2026 . The average Monte Rosa Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Monte Rosa Therapeutics Inc EBITDA forecast 2026. The average Monte Rosa Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Monte Rosa Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Monte Rosa Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.47 | -1.86 |
| 52.04% | 295.74% | |
| P/E | negative | |
| EV/Sales | 8.45 |
9 Analysts have issued a Monte Rosa Therapeutics Inc forecast for earnings per share. The average Monte Rosa Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Monte Rosa Therapeutics Inc...
Current Monte Rosa Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wedbush |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wedbush:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jun 30 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
